海外の治験の状況「1」での検索結果
148件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Authorised
- HIV-1 Attachment Inhibitor comparison in Heavily Treatment Experienced patients
- HIV, Adult MedDRA version: 17.1 Level: PT Classification code 10020161 Term: HIV infection System Organ Class: 10021881 - Infections and infestations ;Therapeutic area: Diseases [C] - Virus Diseases [C02]
- Argentina, Australia, Belgium, Brazil, Canada, Chile, Colombia, Denmark, France, Germany, Greece, Ireland, Italy, Mexico, Netherlands, Norway, Peru, Poland, Portugal, Puerto Rico, Romania, Russian Federation, South Africa, Spain, Taiwan, United Kingdom, United States
- 2015-02-19
Authorised
- A Study of the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease
- Moderately to Severely Active Crohn's Disease MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
- Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Canada, China, Colombia, Croatia, Czech Republic, France, Georgia, Germany, Greece, Hungary, Israel, Italy, Japan, Jordan, Korea, Republic of, Latvia, Lebanon, Lithuania, Macedonia, the former Yugoslav Republic of, Netherlands, New Zealand, Poland, Portugal, Russian Federation, Saudi Arabia, Serbia, Slovakia, South Africa, Spain, Taiwan, Tunisia, Turkey, Ukraine, United Kingdom, United States
- 2018-03-01
Authorised
- A study in which the safety and efficacy of Nefecon is compared with placebo in patients with primary IgA Nephropathy.
- Primary IgA nephropathy patients at risk of developing end stage renal disease MedDRA version: 20.0 Level: LLT Classification code 10069341 Term: Berger's disease System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
- Argentina, Australia, Belarus, Belgium, Canada, Czech Republic, Finland, France, Germany, Greece, Italy, Korea, Republic of, Poland, Spain, Sweden, Taiwan, Turkey, United Kingdom, United States
- 2018-02-21
Authorised
- A study in which the safety and efficacy of Nefecon is compared with placebo in patients with primary IgA Nephropathy.
- Primary IgA nephropathy patients at risk of developing end stage renal disease MedDRA version: 20.0 Level: LLT Classification code 10069341 Term: Berger's disease System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
- Argentina, Australia, Belarus, Belgium, Canada, Czech Republic, Finland, France, Germany, Greece, Italy, Korea, Republic of, Poland, Spain, Sweden, Taiwan, Turkey, United Kingdom, United States
- 2018-02-13
Authorised
- A study in which the safety and efficacy of Nefecon is compared with placebo in patients with primary IgA Nephropathy.
- Primary IgA nephropathy patients at risk of developing end stage renal disease MedDRA version: 20.0 Level: LLT Classification code 10069341 Term: Berger's disease System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
- Argentina, Australia, Belarus, Belgium, Canada, Czech Republic, Finland, France, Germany, Greece, Italy, Korea, Republic of, Poland, Spain, Sweden, Taiwan, Turkey, United Kingdom, United States
- 2018-02-12
Authorised
- An open-label clinical trial of volanesorsen in patients with Familial Chylomicronemia Syndrome (FCS)
- Familial Chylomicronemia Syndrome (FCS) MedDRA version: 20.0 Level: LLT Classification code 10017339 Term: Fredrickson Type I lipidaemia System Organ Class: 100000004850 MedDRA version: 20.0 Level: LLT Classification code 10060593 Term: Fredrickson Type I lipidemia System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
- Brazil, Canada, France, Germany, Israel, Italy, Netherlands, South Africa, Spain, United Kingdom, United States
- 2016-02-26
Authorised
- A study in which the safety and efficacy of Nefecon is compared with placebo in patients with primary IgA Nephropathy.
- Primary IgA nephropathy patients at risk of developing end stage renal disease MedDRA version: 20.0 Level: LLT Classification code 10069341 Term: Berger's disease System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
- Argentina, Australia, Belarus, Belgium, Canada, Czech Republic, Finland, France, Germany, Greece, Italy, Korea, Republic of, Poland, Spain, Sweden, Taiwan, Turkey, United Kingdom, United States
- 2018-03-02
Authorised
- A Clinical Trial for Newly Diagnosed High Risk ER+/HER2– (Estrogen Receptor Positive/ Human Epidermal growth factor receptor Negative) Breast Cancer
- High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2–) Breast Cancer MedDRA version: 20.1 Level: LLT Classification code 10070575 Term: Estrogen receptor positive breast cancer System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Belgium, Brazil, Canada, Colombia, France, Germany, Hungary, Ireland, Israel, Japan, Korea, Republic of, New Zealand, Poland, Portugal, Russian Federation, Spain, Taiwan, Ukraine, United Kingdom, United States
- 2018-10-19
Authorised
- International trial in Philadelphia chromosome-positive acute lymphoblastic leukemia
- Philadelphia positive Acute Lumphoblastic Leukemia MedDRA version: 20.0 Level: PT Classification code 10034877 Term: Philadelphia chromosome positive System Organ Class: 10022891 - Investigations MedDRA version: 20.0 Level: LLT Classification code 10000844 Term: Acute lymphoblastic leukaemia System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Austria, Canada, Chile, Czech Republic, Denmark, European Union, Finland, France, Germany, Hong Kong, Israel, Italy, Netherlands, Poland, Sweden, Switzerland, United Kingdom, United States
- 2017-10-30
Authorised
- International, multicenter, randomized (1:1 oral treprostinil (UT-15C): placebo), double-blind, placebo-controlled study in subjects with Pulmonary Arterial Hypertension (PAH) who are receiving background oral monotherapy
- Pulmonary Arterial Hypertension MedDRA version: 20.0 Level: PT Classification code 10064911 Term: Pulmonary arterial hypertension System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
- Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Denmark, France, Germany, Greece, India, Israel, Italy, Korea, Republic of, Mexico, Netherlands, Poland, Singapore, Sweden, Taiwan, United Kingdom, United States
- 2012-08-01
